|| List of recent Antibodies-related patents
| Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system|
This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression.
| Surface anchored light chain bait antibody display system|
The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. Embodiments of the invention provide a system in which a bait complexed with a monovalent antibody fragment can be captured prior to secretion in a host cell by virtue of surface displaying an antibody light chain and utilizing the covalent interaction of this light chain with the heavy chain of an antibody molecule that is co-expressed in the same host.
Merck Sharp & Dohme Corp.
| Reagents and methods for detecting influenza virus proteins|
Two universally conserved sequences from influenza type a neuraminidases were identified by large scale sequence analysis then chemically modified and conjugated to carrier proteins to generate mono-specific and monoclonal antibodies. The two antibodies, one targeting the n-terminus of the type a neuraminidase and the other sequence close to enzymatic active site, were capable of binding to all 9 subtypes of neuraminidase while demonstrating remarkable specificity against the viral neuraminidase sequences since no cross-reactivity against allantoic proteins was observed.
Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health
| Bag3 as biochemical serum and tissue marker|
The present invention concerns the field of diagnostic biological markers. Specifically the invention relates to anti-bag3 antibodies for use as biological markers for the diagnosis of a pathological state.
| Antibodies against claudin 18.2 useful in cancer diagnosis|
The invention relates to antibodies directed against an epitope located within the c-terminal portion of cldn18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express cldn18.2.. .
Tron- Translationale Onkologie An Der Johannes Gutenberg-universitat Mainz Gemeinnutzige Gmbh
| Method for detecting cancer, and antibody capable of recognizing pancreatic ribonuclease 1|
Pancreatic cancer can be detected using a monoclonal antibody which binds to pancreatic rnase 1 when a site in pancreatic rnase 1 capable of being modified with an n-glycan chain is not linked to a glycan chain, but which does not bind to pancreatic rnase 1 when an n-glycan chain is linked to the site. Also provided is a monoclonal antibody which can bind to pancreatic rnase 1 simultaneously with the binding of the aforementioned antibody to pancreatic rnase 1, and determining the ratio of a to b using the antibodies, wherein a represents the amount of the site located in the pancreatic rnase 1 capable of being modified with an n-glycan chain, wherein an n-glycan chain is linked or not linked to the site; and b represents the amount of the site located in the pancreatic rnase 1 capable of being modified with an n-glycan chain..
| In situ detection of early stages and late stages hpv infection|
Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting hpv infection and hpv related cancer diagnosis, including infection by various hpv genotypes, early and/or late stage hpv-associated or hpv-specific cancers. The anti-hpv antibodies are used in performing immunological assays on clinical samples.
| Method of inducing antibodies to human immunodeficiency virus involving the administration of mper peptide-liposome conjugates|
The present invention relates to a method of inducing the production in a patient of anti-hiv antibodies. The method comprises administering to a patient in need thereof an amount of at least one liposome-peptide conjugate in an amount sufficient to effect that induction.
| Replikin sequences and their antibodies for diagnostics, therapeutics, and vaccines against prion and neurodegenerative disorders including alzheimer's disease|
The present invention provides methods of diagnosing, treating, and preventing prion and neurodegenerative disorders including vaccines against prion diseases and neurodegenerative disorders.. .
| Btla antibodies and uses thereof|
The invention relates to btla antibodies that block btla-hvem interaction and uses thereof.. .
Inserm (institut National De La Sante Et De La Recherche Medicale)
Method of providing disease-specific binding molecules and targets
Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as alzheimer's disease are described..
University Of Zurich
Methods for treating cancer by administering an anti-ang-2 antibody
The present invention provides antibodies that bind to angiopoietin-2 (ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ang-2.
Regeneron Pharmaceuticals, Inc.
Therapeutic methods for peritoneal carcinomatosis
Described herein are methods and medicaments useful for treating peritoneal carcinomatosis by administering anti-ctgf agents, particularly anti-ctgf antibodies. Methods for prognosing individuals with perinoteal carcinomatosis are also provided.
Crystalline anti-human il-23 antibodies
Crystalline forms of antibodies to human il-23, such as antibodies to human il-23p19, are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. In treatment of inflammatory, autoimmune, and proliferative disorders.
Merck Sharp & Dohme Corp.
Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease..
New York University
Anti-rspo antibodies and methods of use
Provided herein are anti-rspo antibodies, in particular anti-rspo2 antibodies and/or anti-rspo3 antibodies, and methods of using the same.. .
Bordetella outer-membrane protein antigens and methods of making and using the same
An isolated protein or peptide selected from the group consisting of bordetella colonization factor a (bcfa) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.. .
Wake Forest University Health Sciences
High-affinity monoclonal antibodies to glypican-3 and use thereof
Described herein is the identification of a panel of high affinity monoclonal antibodies that bind gpc3. The disclosed antibodies recognize native gpc3 on the surface of cancer cells, as well as soluble gpc3.
The United States Of America,as Represented By The Secretary,department Of Health And Human Service
Caninized anti-ngf antibodies and methods thereof
The invention provides novel caninized anti-ngf antibodies (such as caninized anti-ngf antagonist antibodies and antigen binding proteins), and polynucleotides encoding the same. The invention further provides use of said antibodies or antigen binding proteins and/or nucleotides in the treatment and/or prevention of ngf related disorders, particularly pain..
Cd33 antibodies and use of same to treat cancer
The invention provides murine, chimeric, and humanized antibodies that specifically bind to cd33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting cd33..
Seattle Genetics, Inc.
Antibodies against hgf - receptor and uses
antibodies which are antagonists of the human hgf receptor (met), wherein the antibodies specifically bind to amino acid residues 568-741 of human met (seq id no: 1) with high affinity.. .
Cancer Research Technology Limited
Anti-cd70 antibody drug conjugates
This invention relates to anti-cd70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αcd70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αcd70 antibodies of the invention are conjugated to one or more toxins.
Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy
The present invention provide purified flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.. .
Stabilized human igg4 antibodies
A highly stable mutant of human igg4 antibody is provided. Such antibody is an antibody in which the ch3 domain of human igg4 is substituted with the ch3 domain of human igg1 and which exhibits inhibited aggregate formation, an antibody in which the ch3 and ch2 domains of human igg4 are substituted with the ch3 and ch2 domains of human igg1, respectively, or an antibody in which arginine at position 409 indicated in the eu index proposed by kabat et al.
Kyowa Hakko Kirin Co., Ltd
Murine anti-ny-eso-1 t cell receptors
The invention provides an isolated or purified t cell receptor (tcr) having antigenic specificity for ny-eso-1. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions.
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serv.
Il-17 homologous polypeptides and therapeutic uses thereof
The present invention is directed to novel polypeptides having sequence identity with il-17, il-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
Ultra-sensitive detection of extremely low level biological analytes using electrochemical signal amplification and biosensor
This invention allows ultra-low levels of virtually any biological analyte to be detected and quantified rapidly, simply and inexpensively with an electrochemical biosensor using a novel electrochemical signal amplification technique. The invention amplifies detection signals from low level analytes using an innovative sandwich elisa structure that replaces optical labels with a massive amount of electrochemically detectable guanine rich oligonucleotide tags.
Targeted dna enrichment and sequencing
The invention relates to a method for enriching one or more target sequences of a deoxyribonucleic acid (dna) in a composition, comprising the steps of providing a composition comprising one or more deoxyribonucleic acid (dna) molecules, hybridizing to said one or more dna molecules, one or more target specific ribonucleic acid (rna) hybridization probes, thereby forming one or more rna/dna hybrids, capturing the rna/dna hybrids with one or more antibodies being specific for such rna/dna hybrids, thereby forming one or more rna/dna/antibody hybrids, isolating the one or more rna/dna/antibody hybrids, amplifying the one or more dna molecules of the one or more rna/dna/antibody hybrids if necessary, and, optionally, sequencing the one or more dna molecules of the one or more rna/dna/antibody hybrids or the amplification product, wherein the sequencing is preferably done by means of next generation sequencing. The invention also relates to a kit comprising a first an antibody which is specific for a dna/rna hybrid molecule, wherein optionally the antibody is bound to a magnetic particle, and additionally comprising one or more target specific rna hybridization probes..
Monoclonal antibodies that specifically bind to m.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % q mediated diseases..
The Regents Of The University Of California
Antibodies to matrix metalloproteinase 9
The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (mmp9) protein (mmp9 is also known as gelatinase-b), such as where the binding proteins comprise an immunoglobulin (ig) heavy chain (or functional fragment thereof) and an ig light chain (or functional fragment thereof).. .
Gilead Biologics, Inc.
Protein expression analyses for identifying genotoxic compounds
The invention relates to a method for screening compounds with (pro-)genotoxic activity by providing a system being capable of expressing a panel of defined proteins, incubating at least a portion of the system with compounds to be screened, and comparing the expression of the proteins in the system with the protein expression in a control system, thereby detecting the (pro-)genotoxic activity. Another object of the invention concerns a method for monitoring the likelihood of developing a physiological and/or pathological condition, which is caused, mediated and/or propagated by the genetic deregulation of proliferation, differentiation and/or damage repair, in response to a compound administered to a mammal in need of such treatment by determining an expression level of defined proteins in a biological sample withdrawn from the mammal.
Merck Patent Gmbh
Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers
The monoclonal antibodies that only recognise the o-acetylated form of the gd2 ganglioside, or fragments of the antibody, for the diagnosis and the treatment of cancers in which the cells express the o-acetylated gd2, the antibody or the fragment recognising the o-acetylated gd2 molecules expressed by the tumoral cells and not recognising the gd2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. Also artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the o-acetylated gd2..
Universite De Nantes
Il-6 binding molecules
The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of il-6 (e.g., human, mouse and non-human primate il-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to il-6 and inhibit its binding to an il-6 receptor.
Provided is a derivative of 22-hydroxycholesterol, 24s-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative.
Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.
Anti-alpha-synuclein antibodies and methods of use
The invention provides anti-human alpha-synuclein antibodies and methods of using the same.. .
Hoffmann-la Roche Inc.
Tlr3 binding agents
Disclosed herein are anti-tlr3 antibodies as well as methods of making and using them. The antibodies are particularly adapted to the treatment of autoimmune or inflammatory diseases using anti-tlr3 antibodies..
Interferon antagonists, antibodies thereto, and associated methods of use
Described are compositions and methods useful for modulating the immune system of a subject. Also included are diagnostic methods for monitoring an immunologic condition.
Rutgers, The State University Of New Jersey
Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof
Anti-dr5 family member antibodies and bispecific antibodies comprising one or more anti-dr5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on dr5 positive cells..
International - Drug - Development - Biotech
Baff receptor (bcma), an immunoregulatory agent
A novel receptor in the tnf family is provided: baff-r. Chimeric molecules and antibodies to baff-r and methods of use thereof are also provided..
Biogen Idec Ma Inc.
Antibody recognizing human leukemia inhibitory factor (lif) and use of anti-lif antibodies in the treatment of diseases associated with unwanted cell proliferation
The invention relates to antibodies directed against human leukemia inhibitory factor (lif) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease.
Fundacio Privada Institucio Catalana De Recerca I Estudis Avancats (icrea)
Active protease-resistant antibody fc mutants
The present invention relates to modified fc-containing molecules including modified antibodies characterized by increased resistance to host and pathogen-derived proteases, ability to interact with fcγr receptors except with fcγri, and lack of induction of il-10 secretion by macrophages, and methods of using and making them.. .
Janssen Biotech, Inc.
antibodies and antigen binding fragments that specifically binds to siglec-15 are described herein. These antibodies or antigen binding fragments may have the ability of inhibiting differentiation of osteoclasts and/or the ability of inhibiting the bone resorption activity of osteoclasts.
Alethia Biotherapeutics Inc.
Detectors of serum biomarkers for predicting ovarian cancer recurrence
Polypeptide marker antigens for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, each of the polypeptide marker antigens binding specifically to at least one autoantibody marker. An antibody binding assay for detecting the presence of autoantibody biomarkers associated with ovarian cancer recurrence, and methods for performing the assay.
Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
Provided are methods and compositions for clinical treatment of advanced her2 positive solid tumors cancer using combination therapies comprising bispecific anti-erbb2/anti-erbb3 antibodies.. .
Merrimack Pharmaceuticals, Inc.
Radioactive rhodium complexes, preparation methods and uses thereof
The present invention concerns radioactive rhodium complexes, their preparation methods, and their use for the radiolabelling of biomolecules, especially monoclonal antibodies.. .
Universite D' Angers
Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
An in vivo method for detecting α-synuclein protofibrils in human tissue comprises administering an antibody or fragment thereof to a human, wherein the antibody or fragment thereof is labelled with a detectable label, and detecting a complex formed between the antibody or fragment thereof and α-synuclein protofibrils in the human tissue. The antibody or fragment thereof has high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers and has a combination of three specified variable heavy (vh) cdr sequences and three specified variable light (vl) cdr sequences..
Bioarctic Neuroscience Ab
Neo antibodies for diagnostic imaging of tissue injury
A method for diagnosing the development of a tissue injury in a subject comprising administering a sample of neoantibodies to the subject's tissue for the purpose of detecting the presence of neoepitopes bearing complement proteins.. .
Novelmed Therapeutics, Inc.
Crystallization methods for purification of monoclonal antibodies
This application teaches methods for crystallizing antibodies from cell-free culture supernatants. They produce high purity, stable, crystallized monoclonal antibodies suitable for formulation in pharmaceutical products in high yield from cell-free culture supernatant without the use of costly steps or equipment..
Transgenic non-human vertebrate for the in vivo production of dual specificity immunoglobulins or hypermutated heavy chain only immunoglobulins
The invention relates, in one aspect, generally to novel concept of guided selection of antibody variable domains, combination and expression entirely in vivo. An application is to produce multivalent polypeptides.
Single-chain antibodies and other heteromultimers
The invention provides engineered heteromultimeric protein complexes constructed using one, two, or three tethers and methods for making, using, and purifying such complexes, such as antibodies with different binding properties.. .
Methods for determining ligand binding to a target protein using a thermal shift assay
The present invention concerns a method of determining whether a non-purified sample contains a target protein bound to a ligand of interest comprising the steps of a) exposing the non-purified sample to a temperature which is capable of causing or enhancing precipitation of the unbound target protein to a greater extent than it is capable of causing or enhancing precipitation of the target protein bound to the ligand; and b) analysing said sample for the presence of soluble or native target protein using two or more affinity reagents capable of binding to said soluble or native target protein with a higher affinity than to an unfolded and/or insoluble form of said target protein. The invention particularly concerns the use of two affinity reagents (e.g.
Method for the diagnosis of early rheumatoid arthritis
The present invention relates to biomarkers that are specifically recognized by autoantibodies present in a biological of patients with rheumatoid arthritis (ra). The invention provides methods and kits using these biomarkers for the diagnosis of ra, in particular for the diagnosis of early ra..
Vibrio cholerae lipoprotein 15 (lp15) variants as anti-interference additive in tpn17-based immunoassays for detection of anti-treponema antibodies
The invention relates to a method for detecting antibodies against the tpn17 antigen of treponema pallidum in an isolated sample wherein a peptide sequence of vibrio cholerae lipoprotein 15 (vclp15) or a partial sequence thereof is used as a reagent for reduction of interference, i.e. For minimizing false positive results.
Devices, systems, and methods for diagnostic testing
The present disclosure relates to devices, systems, and methods for performing diagnostic tests. The disclosed diagnostic devices are capable of performing analytic tests and communicating with a portable multifunctional device (pmd) or other computing device.
Identification of atypical antibodies in human blood and blood products
A method identifies atypical antibodies in blood or blood product manufacturing processes that may produce false positives in quality control testing on intermediate or final products.. .
Pregnancy-associated plasma protein-a2 (papp-a2) polynucleotides
The present invention provides pregnancy associated plasma protein a2 (papp-a2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode papp-a2, expression vectors for the production of purified papp-a2, antibodies capable of binding specifically to papp-a2, hybridization probes or oligonucleotides for the detection of papp-a2-encoding nucleotide sequences, genetically engineered host cells for the expression of papp-a2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of papp-a2, are also described..
Anti-pancreatic cancer antibodies
Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human pam4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers.
Method for identification of non-hematogeneous karocytes enriched from body fluid of humans or animals
Disclosed is a method for identification of non-hematogenous karyocytes enriched from body fluid of humans or animals, wherein immunofluorescent staining of antibodies against human leukocytes and fluorescence in situ hybridizationof chromosome are carried out synchronously to distinguish hematogenous karyocytes and the interference produced by the hematogenous karyocytes during the judgement on tumour cells is removed effectively, thus achieving efficient and rapid enrichment and extraction from human body fluid of non-hematogenous rare cancer cells originating from the epithelium or not originating from the epithelium and effective identification. The method provided by the present invention does not need to lyse and break red blood cell and without influencing the targeted cell in human body fluid, thus the original cell shape is maintained very well, which is convenient for the subsequent identification and judgement of cells..
Combination gas vaccines and therapeutics
Compositions useful for reducing the risk of, preventing, and/or treating s. Pyogenes (gas) infections which comprise combinations of gas antigens, nucleic acid molecules encoding the antigens, or antibodies which specifically bind to the antigens..
Methods for displaying polypeptides and uses thereof
Provided herein are methods and compositions for displaying a polypeptide on a tubular structure and uses of such displayed polypeptides in the production of antibodies or vaccines.. .
Anti-hiv vaccine constructed based on amino acid mutations in attenuated live eiav vaccine
Provided are antigenic polypeptides of hiv envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of equine infectious anemia virus, dna constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating hiv infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against hiv in organism..
Method of generating human monoclonal antibodies
This invention provides a human antibody, a hybridoma cell line for the production of the antibody, a reconstituted mouse strain for the production of the hybridoma, and methods of producing and using thereof.. .
Mutated anti-tnfa antibodies and methods of their use
The present invention is directed to modified antibodies, including anti-tnfα antibodies, in which c-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“pgk”) to one that includes a proline positioned between the glycine and lysine, resulting in a c-terminal sequence of proline-glycine-proline-lycine (“pgpk”). The invention further provides methods of producing and using such antibodies..
Tgf-beta1 specific antibodies and methods and uses thereof
Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (tgf-β1) are provided, particularly recognizing human and mouse tgf-β1 and not recognizing or binding tgf-β2 or tgf-β3. Particular antibodies are provided which specifically recognize and neutralize tgf-β1.
Monoclonal antibodies against nkg2a
The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of nkg2a receptors on nk cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders..
Anti-il-17f antibodies and methods of use thereof
This invention provides fully human monoclonal antibodies that recognize il-17f and/or the heterodimeric il-17a/il-17f complex, but do not recognize il-17a. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic..
Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tl1a. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same.
Combination therapy using anti-egfr and anti-her2 antibodies
The invention relates to the combined use of anti-egfr antibodies and anti-her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the egfr type and low levels of her2. The invention refers in particular monoclonal antibody “trastuzumab” (herceptin®) directed against the her2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmab 425, emd 72000) directed against egf receptors.
Bispecific antibodies against human tweak and human 1l17 and uses thereof
The present invention relates to bispecific antibodies against human tweak and human il17 (bispecific tweak-il17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. .
Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
The present invention relates to humanized antibodies that specifically bind an ec1 domain of a mammalian cadherin-11 protein and compositions (e.g., pharmaceutical compositions) comprising such antibodies. The invention also relates to methods for treating cadherin-11-mediated disorders in a mammalian subject by administering a therapeutically effective amount of a humanized antibody of the invention.
Methods of preventing or treating pain using anti-ngf antibodies that selectively inhibit the association of ngf with trka, without affecting the association of ngf with p75
Ngf antagonists including antibodies and antibody fragments thereof having binding specificity to human nerve growth factor (“ngf”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an ngf antagonist inhibits the association of ngf with trka without inhibiting the association of ngf with p75.
Methods of antagonizing signal transduction in spinal cord cells using an il-31ra or osmr-b antagonist
Use of antagonists to il-31ra and osmrb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof.
Methods of treating neuronal inflammation using an il-31 monoclonal antibody
Use of antagonists to il-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof.
Methods for treatment of gastric cancer
The application provides methods of detection, diagnosis, prognosis, prophylaxis and treatment of folate receptor-alpha-expressing gastric cancer using antibodies that specifically bind to folate receptor alpha.. .
Anti-cd134 (ox40) antibodies and uses thereof
The invention provides antibodies that specifically bind to human cd134. Invention anti-human cd134 antibodies specifically bind to the extracellular domain of human cd134, including non-ox40 ligand (ox40l) binding domains on human cd134, which is expressed on e.g.
Pancreatic cancer targets and uses thereof
The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (pcat) and antibodies binds to pcat.
Mutant adeno-associated virus virions and methods of use thereof
The present invention provides mutant adeno-associated virus (aav) that exhibit altered capsid properties, e.g., reduced binding to neutralizing antibodies in serum and/or altered heparin binding and/or altered infectivity of particular cell types. The present invention further provides libraries of mutant aav comprising one or more mutations in a capsid gene.
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing cldn18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.. .
Antibodies to il-6 and use thereof
The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for il-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the vh, vl and cdr polypeptides described herein, and the polynucleotides encoding them.
Anti-ly6e antibodies and methods of use
The invention provides anti-ly6e antibodies, immunoconjugates and methods of using the same.. .
Disease therapy by inducing immune response to trop-2 expressing cells
The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.